How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown, Murray, Kirby, S, Skedgel, C ORCID: https://orcid.org/0000-0003-4989-8846, Fisk, J D, Murray, T J, Bhan, V and Sketris, Ingrid (2007) How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, 69 (15). pp. 1498-507. ISSN 0028-3878

Full text not available from this repository. (Request a copy)

Abstract

Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset (R-onset) definite MS patients under "real-world" conditions.

Item Type:	Article
Uncontrolled Keywords:	adult,antirheumatic agents,clinical trials as topic,cohort studies,data interpretation, statistical,databases as topic,disability evaluation,disease progression,female,humans,male,middle aged,models, statistical,multiple sclerosis, chronic progressive,multiple sclerosis, relapsing-remitting,nova scotia,secondary prevention,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	04 Feb 2015 12:36
Last Modified:	20 Oct 2022 22:33
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51939
DOI:	10.1212/01.wnl.0000271884.11129.f3

Actions (login required)

View Item